Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin glulisine.

Dean M Robinson1, Keri Wellington

  • 1Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs
|May 19, 2006
PubMed
Summary
This summary is machine-generated.

Insulin glulisine effectively manages blood glucose in diabetes patients, offering rapid action and comparable glycemic control to other insulins. Its safety profile is similar to regular human insulin and insulin lispro, with comparable rates of severe hypoglycemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.

Drugs·2009
Same author

Aprepitant: a review of its use in the prevention of nausea and vomiting.

Drugs·2009
Same author

Eslicarbazepine acetate.

CNS drugs·2008
Same author

Mosapride in gastrointestinal disorders.

Drugs·2008
Same author

Rosuvastatin: a review of its effect on atherosclerosis.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2008
Same author

Nilotinib.

Drugs·2008
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Insulin glulisine is a rapid-acting insulin analogue.
  • It offers a faster onset and shorter duration compared to regular human insulin (RHI).

Purpose of the Study:

  • To evaluate the efficacy and safety of insulin glulisine in patients with type 1 and type 2 diabetes mellitus.
  • To compare its glycemic control and post-prandial glucose management against RHI and insulin lispro.

Main Methods:

  • Large, well-designed clinical trials were conducted in patients with type 1 and type 2 diabetes.
  • Glycemic control was assessed by glycosylated hemoglobin (HbA1c) levels and 2-hour post-prandial glucose measurements.

Main Results:

  • Insulin glulisine demonstrated similar glycemic control (HbA1c) to RHI and insulin lispro in type 1 diabetes.

Related Experiment Videos

  • It showed greater reductions in HbA1c and post-prandial glucose levels compared to RHI in type 2 diabetes.
  • The safety profile was comparable to RHI and insulin lispro, with similar rates of severe hypoglycemia.

    • Conclusions:

    • Insulin glulisine is efficacious in controlling prandial blood glucose levels in patients with type 1 and type 2 diabetes.
    • It provides a valuable therapeutic option for diabetes management with a well-established safety profile.